- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | Ono Pharmaceutical Q2 GAAP EPS of ¥95.60, revenue of ¥232.5B | 12 | Seeking Alpha | ||
| 29.10. | Ono Pharmaceutical Co Ltd. H1 Profit Rises | 4 | RTTNews | ||
| 09.10. | Biohaven partners with Ono in $100m IgG degrader deal | 1 | Pharmaceutical Technology | ||
| 08.10. | Biohaven, Ono Pharma Partner to Commercialize IgG Degrader for Graves' Disease | 1 | Contract Pharma | ||
| 08.10. | Biohaven licenses IgG degrader portfolio to Japan's Ono | 1 | Seeking Alpha | ||
| 08.10. | Ono Pharmaceutical to pay Biohaven $80mn upfront for Asian rights to Graves' disease drug | 3 | Tokyo Brief | ||
| ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 08.10. | Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave's asset | 1 | FierceBiotech | ||
| 08.10. | Biohaven Ltd.: Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease | 473 | PR Newswire | Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including... ► Artikel lesen | |
| 16.09. | BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms | 10 | FiercePharma | ||
| 02.09. | Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology | 1 | Pharmaceutical Technology | ||
| 07.08. | Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments | 1 | Pharmaceutical Technology | ||
| 06.08. | Mediar and Ono to Develop Novel Treatments Targeting Fibro-Inflammatory Diseases | 1 | Contract Pharma | ||
| 31.07. | Ono Pharmaceutical GAAP EPS of ¥ 51.38, revenue of ¥ 116.1B | 1 | Seeking Alpha | ||
| 31.07. | Ono Pharmaceutical Co Ltd. Q1 Income Advances | 1 | RTTNews | ||
| 27.07. | Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline | 4 | Zacks | ||
| 27.07. | Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength? | 1 | Zacks | ||
| 28.05. | Jefferies raises Ono Pharmaceutical price target on pipeline outlook | 4 | Investing.com | ||
| 26.03. | Ono Pharma Submits Application For Manufacturing And Marketing Approval Of Ripretinib | 606 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical (4528.T) announced that it has submitted an application for the manufacturing and marketing approval of ripretinib or DCC-2618, developed... ► Artikel lesen | |
| 02.02. | Ono Pharmaceutical Co. Ltd. Reveals Climb In Nine Months Bottom Line | 616 | AFX News | TOKYO (dpa-AFX) - Ono Pharmaceutical Co. Ltd. (OPHLF) released a profit for its nine months that Increases, from the same period last yearThe company's earnings came in at JPY68.949 billion... ► Artikel lesen | |
| 14.01. | Ono Pharma Taiwan Receives Additional Approval Of Opdivo In Combination With Ipilimumab | 651 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical Co. announced that Ono Pharma Taiwan Co., a Taiwanese subsidiary of Ono, received the additional approval of Opdivo Intravenous Infusion... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 153,28 | +0,14 % | Gilead erwartet FDA-Entscheidung über neue Zelltherapie - Mesoblast will Behandlung auf Erwachsene ausweiten | ||
| CANOPY GROWTH | 0,539 | +1,32 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| MERCK & CO | 131,86 | -0,57 % | Merck & Co. (MRK): US-Pharmagigant bereitet die nächste Rally vor! | Befreiungsschlag an der Widerstandslinie? Rückblick Im Chart sehen wir nach einer Seitwärtsphase einen steilen Anstieg bis August. Darauf folgte eine Konsolidierung. Die Bullen lauern nun knapp unterhalb... ► Artikel lesen | |
| JAGUAR HEALTH | 0,437 | +0,07 % | Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders | SAN FRANCISCO, CA / ACCESS Newswire / November 6, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's November 6, 2026 Special Meeting... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 387,40 | -0,08 % | Madrigal Pharmaceuticals: H.C. Wainwright bekräftigt Kaufempfehlung gestützt auf starke Marktposition | ||
| IQVIA | 247,50 | +0,41 % | ROUNDUP: IQVIA Holdings Boosts FY26 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Tuesday, life sciences services company IQVIA Holdings Inc. (IQV) raised its adjusted earnings and revenue guidance... ► Artikel lesen | |
| AZENTA | 36,400 | 0,00 % | Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026. | Q4'26 reported revenue growth of 5% year over year and 2% on an organic basisFY'26 reported revenue growth of 5% year over year and 2% on an organic basisFY'27 reported revenue expected to range from... ► Artikel lesen | |
| ALMIRALL | 10,700 | +0,75 % | Almirall, S.A.: Almirall 9M 2026 Results | Almirall continues to deliver solid results at 9M 2026, growing its European Dermatology business 17.6% YoY, increasing total Net Sales by 8.3%, and EBITDA by 22.7% reiterating full-year guidance... ► Artikel lesen | |
| PROTHENA | 7,722 | +0,76 % | Prothena Corporation plc: Prothena Reports Third Quarter 2026 Financial Results and Business Highlights | Net cash used in operating and investing activities was $12.0 million in the third quarter and net cash used in operating and investing activities was $8.9 million for the first nine months of... ► Artikel lesen | |
| SPROUTLY CANADA | - | - | CSE Bulletin: Delist - Sproutly Canada Inc. (SPR) | Le 22 mai/May 2026
The common shares of Sproutly Canada Inc will be delisted from the CSE at market close today, May 22, 2026.
Sproutly Canada Inc. is currently suspended. See Bulletin 2022-0908.
___________________________
Les... ► Artikel lesen | |
| PETIQ | - | - | PetIQ Acquires MYOS To Expand Pet Muscle Health And Mobility Portfolio | ||
| FUJI PHARMA | 10,500 | -1,87 % | Fuji Pharma Co Ltd Full Year Profit Declines | ||
| FINANCIERE DE TUBIZE | 244,60 | +0,08 % | Financière de Tubize SA: Financière de Tubize - 2026 half-year financial report | Half-year financial report 2026Regulated information 1 August 2026
The board of directors of Financière de Tubize has established the 2026 half-year report. This report is available on the website... ► Artikel lesen | |
| BAYER | 56,52 | -0,98 % | Machtwechsel in den USA! Warum Bayer boomt, TeamViewer massiv einbricht und Almonty Industries vor einer massiven Rally stehen könnte! | Machtwechsel in Washington: Die Demokraten haben bei den US-Zwischenwahlen den Senat zurückerobert und wohl auch das Repräsentantenhaus. Für Donald Trump bedeutet das geteilte Macht für den Rest seiner... ► Artikel lesen | |
| MERCK KGAA | 151,15 | +1,21 % | Merck KGaA erhält US-Zulassung für TGCT-Medikament Pimjetmi | DJ Merck KGaA erhält US-Zulassung für TGCT-Medikament Pimjetmi
DOW JONES--Merck kann sein Medikament Pimjetmi (Pimicotinib) künftig auch in den USA vermarkten. Wie der Darmstädter Technologie-... ► Artikel lesen |
Das Unternehmen ONO PHARMACEUTICAL CO LTD ADR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 4,500 Euro und damit 0,00 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONO PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.